FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia
-- Approval provides patients with schizophrenia the ability to access the
efficacy and safety profile of oral aripiprazole in a once-monthly
formulation
-- Relapse prevention is an important consideration in the treatment of
patients with schizophrenia; Abilify Maintena(TM) met the phase III
clinical trial primary endpoint of significantly delaying time to relapse
-- Abilify Maintena will be the first commercialized product from the global
alliance be
Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news